Cubicin indicated for children
Cubicin (daptomycin; Novartis) is now indicated for the treatment of paediatric patients (aged 1–17 years) with complicated skin or soft-tissue infections. Further changes to the summary of product characteristics reflect this addition.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200282
Recommended from Pharmaceutical Press